Inhibitory Indirect Response PK-PD Models (Ep. 34)
In this episode I describe inhibitory indirect response PK-PD models. I describe how they work, how to set up the dataset for NONMEM, and how to code the model in NONMEM. This is the third of 4 episod...
23 Syys 202434min
Effect compartment PK-PD models (Ep. 33)
In this episode I describe effect compartment PK-PD models. I describe how they work, a method of creating exploratory plots, how to set up the dataset for NONMEM, and how to code the model in NONMEM....
9 Syys 202429min
Direct effect PKPD models (Ep. 32)
In this episode I describe direct effect PK-PD models. I describe how they work, a method of creating exploratory plots to identify direct effect models, how to set up the dataset for NONMEM, and how ...
26 Elo 202431min
What should you use to present PK results? (Ep. 31)
In this episode I discuss different methods of presenting pharmacokinetic and pharmacometrics results. I spoke about using PowerPoint and R Markdown derived HTML files. While I prefer HTML files in ne...
12 Elo 202431min
How important is terminal rate constant? (Ep. 30)
This episode covers the terminal elimination rate constant calculated using non-compartmental analysis techniques. I reviewed how the rate constant is used to estimate half-life and extrapolate AUC to...
22 Heinä 202426min
Parellelization in modeling (Ep. 29)
This episode covered parallelization in modeling analyses. I spoke about across model parallelization and within model parallelization. I recommended some approaches for choosing how many cores to use...
8 Heinä 202418min
Residual errors and submission packages (Ep. 28)
Today I covered 2 different topics. First, I spoke about residual error models when modeling. I discussed additive, proportional, and power models. I also reviewed combined models and when they can be...
24 Kesä 202427min
Simulations (Ep. 27)
This episode discusses simulations. I group simulations into 4 categories: (1) average response, (2) population, (3) individual, and (4) clinical trial simulations. I discuss details of each of these ...
10 Kesä 202420min
